Supplemental material
Expert Review of Vaccines
Volume 17, 2018 - Issue 6
Review
Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution
, , , 
&
Christopher ClarkeGlobal Medical Affairs, GSK, Wavre, Belgiumhttps://orcid.org/0000-0001-5539-5319View further author information
https://orcid.org/0000-0001-5539-5319View further author information & Related Research Data
Pneumococcal infection in adults: burden of disease
Source:
Elsevier BV
Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: Review of evidence on indirect effects
Source:
Elsevier BV
Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis
Source:
Public Library of Science (PLoS)
Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
Source:
Public Library of Science (PLoS)
Laboratory Medicine in Africa: A Barrier to Effective Health Care
Source:
Oxford University Press (OUP)
Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-type Invasive Pneumococcal Disease Among Young Children
Source:
Ovid Technologies (Wolters Kluwer Health)
The 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Coadministered With DTPw-HBV/Hib and Poliovirus Vaccines: Assessment of Immunogenicity
Source:
Ovid Technologies (Wolters Kluwer Health)
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Source:
Ovid Technologies (Wolters Kluwer Health)
Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study
Source:
Elsevier BV
WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26–27 October 2006, Geneva
Source:
Elsevier BV
Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
Source:
Public Library of Science (PLoS)
Impact of the Conjugation Method on the Immunogenicity ofStreptococcus pneumoniaeSerotype 19F Polysaccharide in Conjugate Vaccines
Source:
American Society for Microbiology
Response to Primary and Booster Vaccination With 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine in Korean Infants
Source:
Ovid Technologies (Wolters Kluwer Health)
Systematic Review of the Indirect Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Pneumococcal Disease and Colonization
Source:
Ovid Technologies (Wolters Kluwer Health)
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial
Source:
Elsevier BV
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
Source:
Elsevier BV
Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites
Source:
Public Library of Science (PLoS)
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
Source:
Elsevier BV
Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study
Source:
Elsevier BV
Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?
Source:
Elsevier BV
Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study
Source:
Elsevier BV
Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution
Source:
Taylor & Francis
Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution
Source:
Taylor & Francis
PCV13 Impact Evaluations
Source:
Ovid Technologies (Wolters Kluwer Health)
A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children
Source:
Ovid Technologies (Wolters Kluwer Health)
A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection
Source:
New England Journal of Medicine (NEJM/MMS)
Serotype replacement in disease after pneumococcal vaccination
Source:
Elsevier BV
Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada
Source:
Elsevier BV
Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review
Source:
Public Library of Science (PLoS)
Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway
Source:
Elsevier BV
Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
Source:
Oxford University Press (OUP)
Vaccine effectiveness of PCV13 in a 3 + 1 vaccination schedule
Source:
Elsevier BV
Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease.
Source:
Elsevier BV
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
Source:
Ovid Technologies (Wolters Kluwer Health)
Which Pneumococcal Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine Formulation and Use, Part I
Source:
Oxford University Press (OUP)
10-valent pneumococcal nontypeableHaemophilus influenzaePD conjugate vaccine: Synflorix™
Source:
Informa UK Limited
Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012
Source:
Elsevier BV
Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children
Source:
Ovid Technologies (Wolters Kluwer Health)
Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children
Source:
Elsevier BV
Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.
Source:
Elsevier BV
Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
Source:
Public Library of Science (PLoS)
Impact of pneumococcal conjugate vaccines for children in high- and non–high-income countries
Source:
Informa UK Limited
SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF THE 10-VALENT PNEUMOCOCCAL NONTYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE COADMINISTERED WITH DTPW-HBV/HIB AND POLIOVIRUS VACCINES
Source:
Ovid Technologies (Wolters Kluwer Health)
Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution
Source:
Taylor & Francis
Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations.
Source:
Oxford University Press (OUP)
Pneumococcal Capsules and Their Types: Past, Present, and Future.
Source:
American Society for Microbiology
Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) When Coadministered With Different Neisseria meningitidis Serogroup C Conjugate Vaccines
Source:
Ovid Technologies (Wolters Kluwer Health)
Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project.
Source:
Public Library of Science (PLoS)
The Contribution of Specific Pneumococcal Serogroups to Different Disease Manifestations: Implications for Conjugate Vaccine Formulation and Use, Part II
Source:
Oxford University Press (OUP)
Long-term Impact of a “3 + 0” Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002–2014
Source:
Oxford University Press (OUP)
Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?
Source:
Springer Nature
A dynamic model of pneumococcal infection in the United States: Implications for prevention through vaccination
Source:
Elsevier BV
Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough
Source:
Informa UK Limited
Effects of Vaccination on Invasive Pneumococcal Disease in South Africa
Source:
New England Journal of Medicine (NEJM/MMS)
Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature
Source:
Elsevier BV
Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany
Source:
Elsevier BV
Challenges in Estimating the Impact of Pneumococcal Conjugate Vaccines Through Surveillance
Source:
Ovid Technologies (Wolters Kluwer Health)
Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study
Source:
Elsevier BV
Interim results of an ecological experiment — Conjugate vaccination against the pneumococcus and serotype replacement
Source:
Informa UK Limited
Practice guideline for the management of infants and children 0 to 36 months of age with fever without source
Source:
Elsevier BV
Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study
Source:
Elsevier BV
Linking provided by
